Sofia Bartlett
Sofia Bartlett
British Columbia Centre for Disease Control, University of British Columbia
Verified email at - Homepage
Cited by
Cited by
The influence of hepatitis C virus genetic region on phylogenetic clustering analysis
FMJ Lamoury, B Jacka, S Bartlett, RA Bull, A Wong, J Amin, J Schinkel, ...
PloS one 10 (7), e0131437, 2015
Demonstration of near-elimination of hepatitis C virus among a prison population: the Lotus Glen Correctional Centre hepatitis C treatment project
SR Bartlett, P Fox, H Cabatingan, A Jaros, C Gorton, R Lewis, E Priscott, ...
Clinical Infectious Diseases 67 (3), 460-463, 2018
Sequencing of hepatitis C virus for detection of resistance to direct‐acting antiviral therapy: A systematic review
SR Bartlett, J Grebely, AA Eltahla, JD Reeves, AYM Howe, V Miller, ...
Hepatology communications 1 (5), 379-390, 2017
Moving towards hepatitis C microelimination among people living with human immunodeficiency virus in Australia: the CEASE Study
M Martinello, J Yee, SR Bartlett, P Read, D Baker, JJ Post, R Finlayson, ...
Clinical Infectious Diseases 71 (6), 1502-1510, 2020
The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: impact of direct acting antivirals
SR Bartlett, A Yu, N Chapinal, C Rossi, Z Butt, S Wong, M Darvishian, ...
Liver International 39 (12), 2261-2272, 2019
A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies
SR Bartlett, JO Wertheim, RA Bull, GV Matthews, FMJ Lamoury, ...
Journal of viral hepatitis 24 (5), 404-411, 2017
Addressing the syndemic of HIV, hepatitis C, overdose, and COVID-19 among people who use drugs: the potential roles for decriminalization and safe supply
M Bonn, A Palayew, S Bartlett, TD Brothers, N Touesnard, M Tyndall
Journal of studies on alcohol and drugs 81 (5), 556-560, 2020
Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre‐and post‐universal access to direct‐acting antiviral treatment in …
S Bajis, J Grebely, B Hajarizadeh, T Applegate, AD Marshall, ...
Journal of viral hepatitis 27 (3), 281-293, 2020
Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations
C Rossi, D Jeong, S Wong, G McKee, ZA Butt, J Buxton, J Wong, ...
Journal of hepatology 71 (6), 1116-1125, 2019
Real-world effectiveness of sofosbuvir/velpatasvir for treatment of chronic hepatitis C in British Columbia, Canada: a population-based cohort study
J Wilton, S Wong, A Yu, A Ramji, D Cook, ZA Butt, M Alvarez, M Binka, ...
Open forum infectious diseases 7 (3), ofaa055, 2020
HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection
SR Bartlett, B Jacka, RA Bull, F Luciani, GV Matthews, FMJ Lamoury, ...
Infection, Genetics and Evolution 37, 252-258, 2016
Loss to follow‐up: a significant barrier in the treatment cascade with direct‐acting therapies
M Darvishian, S Wong, M Binka, A Yu, A Ramji, EM Yoshida, J Wong, ...
Journal of viral hepatitis 27 (3), 243-260, 2020
Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir as a hepatitis C virus infection salvage treatment
N Janjua, J Wilton, D Cook, S Wong, Z Butt, S Bartlett, M Pearce, A Ramji, ...
Journal of Hepatology 73, S356-S357, 2020
A latent class approach to identify multi‐risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015
SR Bartlett, TL Applegate, BP Jacka, M Martinello, FMJ Lamoury, M Danta, ...
Journal of the International AIDS Society 22 (2), e25222, 2019
Interferon λ 3 and 4 genotyping using high-resolution melt curve analysis suitable for multiple clinical sample types
FMJ Lamoury, S Bartlett, B Jacka, B Hajarizadeh, J Grebely, GV Matthews, ...
The Journal of molecular diagnostics 17 (5), 583-589, 2015
Identification of critical residues in the bifunctional phosphoenolpyruvate synthetase kinase/phosphotransferase of Escherichia coli
S Bartlett, J Seeliger, JN Burnell
Current Topics in Biochemical Research 14, 77-83, 2012
Drug-related deaths in a population-level cohort of people living with and without hepatitis C virus in British Columbia, Canada
H Samji, A Yu, S Wong, J Wilton, M Binka, M Alvarez, S Bartlett, M Pearce, ...
International Journal of Drug Policy 86, 102989, 2020
Hepatitis C Virus Prevalence, Screening, and Treatment Among People Who Are Incarcerated in Canada: Leaving No One Behind in the Direct‐Acting Antiviral Era
SR Bartlett, J Buxton, A Palayew, CA Picchio, NZ Janjua, N Kronfli
Clinical Liver Disease 17 (2), 75, 2021
Disparities in hepatitis C care across Canadian provincial prisons: implications for hepatitis C micro-elimination
N Kronfli, C Dussault, S Bartlett, D Fuchs, K Kaita, K Harland, B Martin, ...
Canadian Liver Journal, e20200035, 2021
“The Times They Are a-Changin’”: Addressing Common Misconceptions About the Role of Safe Supply in North America’s Overdose Crisis
M Bonn, A Palayew, S Bartlett, TD Brothers, N Touesnard, M Tyndall
Journal of studies on alcohol and drugs 82 (1), 158-160, 2021
The system can't perform the operation now. Try again later.
Articles 1–20